Back to top

Wedbush Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Viridian Therapeutics, with a price target of $43.00. Chico covers ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viridian Therapeutics, Inc. (VRDN)